Analysis Pharmacovigilance

EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams

EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.

VigiEye editorial · Fri 20 Nov 2026

What happened

On 19 November 2026 the EMA published the outcome of a periodic safety update report single assessment (PSUSA) for cytomegalovirus immunoglobulin. The regulatory outcome is recorded as maintenance, so the marketing authorisations covered by the procedure are to stay in place.

The published record is brief. It does not say which safety data were reviewed, whether any signal was discussed, or whether the product information will change. The EMA's procedure page is the place to check for the full wording and any annexes. Until then, the only firm conclusion is that this review did not end in a variation, suspension or revocation of the authorisations.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →